Skin

FDA Approves First Medication to Treat Severe Frostbite

Retrieved on: 
Wednesday, February 14, 2024

SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Key Points: 
  • SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation.
  • Iloprost's efficacy in treating severe frostbite was primarily established in an open-label, controlled trial that randomized 47 adults with severe frostbite, who all received aspirin by vein and standard of care, into one of three treatment groups.
  • The two other groups received other medications that are unapproved for frostbite, given with iloprost (Group 2) or without iloprost (Group 3).

John Legend's Inclusive Personal Care Brand LOVED01 Debuts in the Amazon Beauty Store

Retrieved on: 
Wednesday, February 14, 2024

LOS ANGELES, Feb. 14, 2024 /PRNewswire/ -- LOVED01, the personal care brand created by Grammy award-winning singer-songwriter and entrepreneur John Legend—formulated for melanin-rich skin and beyond—celebrates its first anniversary by launching today in the Amazon Beauty store. Offering effective and affordable skin care, LOVED01's functional line of dermatologist-approved formulas are crafted to nourish, moisturize, and gently balance pH, leaving skin glowing, vibrant, and beautiful. The award-winning collection of skin care products is now available to Amazon customers at amazon.com/loved01. Prime members get fast, free shipping on every order.

Key Points: 
  • The line of award-winning skincare products formulated for melanin-rich skin is collaborating with Amazon Beauty as the brand celebrates its one-year anniversary.
  • LOS ANGELES, Feb. 14, 2024 /PRNewswire/ -- LOVED01, the personal care brand created by Grammy award-winning singer-songwriter and entrepreneur John Legend—formulated for melanin-rich skin and beyond—celebrates its first anniversary by launching today in the Amazon Beauty store.
  • The award-winning collection of skin care products is now available to Amazon customers at amazon.com/loved01 .
  • Bringing LOVED01 to the Amazon Beauty store furthers the brand's mission of providing efficacious, luxury skin care at an affordable price point, available where customers shop every day.

Revieve® and Debenhams Redefine UK Beauty Standards with Groundbreaking AI and AR-Powered Consultation Experiences

Retrieved on: 
Wednesday, February 14, 2024

This partnership is poised to redefine beauty standards in the UK, embarking on a transformative digital journey, fuelled by cutting-edge AI technology and consumer-centric experiences to provide consumers with tailored skincare, haircare, and makeup recommendations.

Key Points: 
  • This partnership is poised to redefine beauty standards in the UK, embarking on a transformative digital journey, fuelled by cutting-edge AI technology and consumer-centric experiences to provide consumers with tailored skincare, haircare, and makeup recommendations.
  • Leveraging Revieve's platform empowers Debenhams' customers to embrace their unique beauty preferences, unlocking the full potential of personalisation through an extraordinary and transformative beauty journey.
  • Whether delving into skincare, makeup, or haircare, Debenhams' customers can now immerse themselves in a customised consultation that feels as though a dedicated beauty expert is guiding them.
  • We eagerly anticipate introducing the future of beauty retailing to our valued customers, setting fresh standards, and enriching their beauty exploration journey," said Alexandra Scolding, Director of Beauty at Debenhams.

Treat Your "Sole" and "Sole-mate" This Valentine's Day with Kerasal®

Retrieved on: 
Wednesday, February 14, 2024

This Valentine's Day and every day after, pamper yourself and your loved ones with the at-home 'spa foot vacation' that will leave your feet extra attractive and silky-smooth, guaranteed to make that special Valentine's Day– and night– much more enjoyable.

Key Points: 
  • This Valentine's Day and every day after, pamper yourself and your loved ones with the at-home 'spa foot vacation' that will leave your feet extra attractive and silky-smooth, guaranteed to make that special Valentine's Day– and night– much more enjoyable.
  • "During these cold winter months, struggling with dry and cracked feet is very common," says Whitney Kopp, Kerasal Brand Lead.
  • Treat yourself and your loved ones to a Valentine's Day experience that even Cupid himself could not resist!
  • The Find Your "Sole-mate" Kerasal Valentine's Day Collection includes:
    Kerasal® Intensive Foot Repair™ Ointment offers visible results in just 1 day.

GLO24K 6-IN-1 Beauty Therapy Wand - A Spa-at-Home LED Beauty Device - Is the Ultimate Solution for All Your Skin Care Needs

Retrieved on: 
Wednesday, February 14, 2024

ATLANTA, Feb. 14, 2024 /PRNewswire/ -- GLO24K, a global beauty brand based in the USA, is introducing a new and revolutionary LED Beauty Device: GLO24K 6-IN-1 Beauty Therapy Wand.

Key Points: 
  • ATLANTA, Feb. 14, 2024 /PRNewswire/ -- GLO24K, a global beauty brand based in the USA, is introducing a new and revolutionary LED Beauty Device: GLO24K 6-IN-1 Beauty Therapy Wand.
  • This 6-In-1 Beauty Wand is an advanced LED Beauty Device for the face, neck, and around the eyes that is loaded with cutting-edge technologies to deliver anti-aging results.
  • In 2021 GLO24K expanded its portfolio and added the hottest trend in the beauty category: LED Beauty Devices.
  • GLO24K 6-IN-1 Beauty Therapy Wand utilizes that same LED Technology to be established as any beauty enthusiast's source for all skin care needs.

Don’t let ‘FDA-approved’ or ‘patented’ in ads give you a false sense of security

Retrieved on: 
Wednesday, February 14, 2024

Having a patent means only that you can stop others from making, using, selling or importing your invention.

Key Points: 
  • Having a patent means only that you can stop others from making, using, selling or importing your invention.
  • For one thing, the law could make it easier for groups of consumers to sue in federal courts over misleading ads.
  • The Federal Trade Commission could also place more of a burden on companies to prove their ads are honest.
  • At a time when ads are everywhere and Americans are losing trust in institutions – and each other – the stakes for truthful product claims are high.

Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Retrieved on: 
Wednesday, February 14, 2024

VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.

Key Points: 
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.
  • VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.
  • On May 24, 2022, Dermavant announced the FDA approved VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

In a Historic Move Beagle Freedom Project Closes Animal Testing Laboratory in Nowata, Oklahoma and Rescues Over 200 Dogs and Cats from Certain Death

Retrieved on: 
Wednesday, February 14, 2024

Beagle Freedom Project has now taken over the 30-acre Nowata, Oklahoma property and facilities where animals were previously held captive, and is transforming the space into Freedom Fields, a rescue, rehabilitation, and adoption center.

Key Points: 
  • Beagle Freedom Project has now taken over the 30-acre Nowata, Oklahoma property and facilities where animals were previously held captive, and is transforming the space into Freedom Fields, a rescue, rehabilitation, and adoption center.
  • More than 200 dogs and cats have been surrendered from this now closed laboratory, and liberated from a lifetime of toxic and painful testing, and they are safe with BFP.
  • Freedom Fields is where dogs, cats, rabbits and farm animals Beagle Freedom Project rescues from animal testing and experimentation will receive thorough medical care, nutritious food, safe and beautiful habitats, space to roam, and all the protection, love, play, enrichment, and freedom they have been deprived of their entire lives.
  • Rehabilitated animals will be carefully matched to foster and adoptive families by BFP’s dedicated adoption coordination team.

A secret war between cane toads and parasitic lungworms is raging across Australia

Retrieved on: 
Wednesday, February 14, 2024

When the first cane toads were brought from South America to Queensland in 1935, many of the parasites that troubled them were left behind.

Key Points: 
  • When the first cane toads were brought from South America to Queensland in 1935, many of the parasites that troubled them were left behind.
  • But deep inside the lungs of at least one of those pioneer toads lurked small nematode lungworms.

An eternal arms race

  • Parasites and their hosts are locked into an eternal arms race.
  • But at the same time, any new trick that enables a host to detect, avoid or repel the parasites is favoured as well.
  • So it’s a case of parasites evolving to infect, and hosts evolving to defeat that new tactic.

The march of the toads

  • But when hosts invade new territory, it can play havoc with the evolutionary matching between local hosts and parasites.
  • The Queensland toads are homebodies and spend their lives in a small area, often reusing the same shelter night after night.
  • For a lungworm larva, having lots of toads in a small area, reusing and sharing shelter sites, makes it simple to find a new host.

Lungworms from the invasion front

  • To understand how this co-evolution is playing out between cane toads and their lungworms, we did some experiments pairing hosts and parasites from different locations in Australia.
  • What would happen when toad and lungworm strains that had been separated by 90 years of invasion were reintroduced to each other?
  • Read more:
    In the evolutionary arms race between cane toads and lungworms, skin secretions play a surprising role


Lee A Rollins receives funding from the Australian Research Council. Rick Shine receives funding from the Australian Research Council. Greg Brown does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

Retrieved on: 
Tuesday, February 13, 2024

HALIFAX, Nova Scotia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the third quarter of its fiscal year 2024, which ended on December 31, 2023. All figures are stated in Canadian dollars unless otherwise stated.

Key Points: 
  • In September 2023, Appili announced the FDA approval of LIKMEZ™ (ATI-1501) , our proprietary taste-masked liquid suspension reformulation of metronidazole, through our U.S. partner, Saptalis Pharmaceuticals LLC.
  • Collaborating with Saptalis, Appili earned US$600,000 in milestone payments in fiscal 2024.
  • Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects to receive feedback in early 2024.
  • As of February 13, 2024, the Company had 121,266,120 issued and outstanding Common Shares, 7,957,000 stock options, and 44,856,874 warrants outstanding.